



LIBRARIES
UNIVERSITY OF WISCONSIN - MADISON

Viokase advertisement.

[s.l.]: [s.n.], 1977

<https://digital.library.wisc.edu/1711.dl/G667YB7HVD2DU8A>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

Viokase® costs your patients less than other pancreatic preparations

4x N.F. Protease
6x N.F. Amylase
10 x N.F. Lipase
(whole pancreas)

Twenty- Five Year Veteran



in digestive management of cystic fibrosis

"We have used pancreatin (Viokase) in powder or tablet form as an effective product since 1951... The initiation of dietary and pancreatic replacement therapy prior to or with the appearance of early signs of gastrointestinal involvement in the absence of pulmonary symptoms permits nearly normal growth and development. It will diminish the usual complaints of frequent, loose, foul movements, protuberant abdomen and excessive appetite, it will markedly reduce the incidence of rectal prolapse and possibly secondary fecal impaction which may result in intestinal obstruction."*

*Shwachman, H., Redmond, A. and Khaw, K-T: "Studies in Cystic Fibrosis—Report of 130 Patients Diagnosed Under 3 Months of Age Over a 20-Year Period"; *Pediatrics*, 46: 335, 1970.

VIOKASE® (pancreatin)

Description: VIOKASE is a pancreatic enzyme concentrate of porcine origin containing standardized amylase, protease and lipase activities plus esterases, peptidases, nucleases and elastase.

The enzyme potency of the tablets and powder are:

| | Each 325 mg. Tablet | Each 0.75 gram ($\frac{1}{2}$ teaspoonful) |
|----------------------|------------------------|--|
| Lipase, N.F. Units | 6,500 | 15,000 |
| Protease, N.F. Units | 32,000 | 75,000 |
| Amylase, N.F. Units | 48,000 | 112,500 |

Under conditions of the N.F. test method (in vitro) VIOKASE has the following total digestive capacity:

| | Each 325 mg. Tablet | Each 0.75 g. Powder |
|-----------------|------------------------|------------------------|
| Dietary Fat | 23 | 53 grams |
| Dietary Protein | 32 | 75 grams |
| Dietary Starch | 48 | 112 grams |

VIOKASE Tablets are not enteric coated.

Indications: As a digestive aid in cystic fibrosis and in exocrine pancreatic deficiencies usually due to chronic pancreatitis, pancreatectomy or obstruction in the pancreas caused by malignant growth.

Administration and Dosage:

Powder: Dosage to patients with cystic fibrosis: $\frac{1}{2}$ teaspoon (0.75 grams) with meals.

Tablets: Dosage to patients with cystic fibrosis or chronic pancreatitis—1 to 3 tablets with meals. For aiding digestion in patients with pancreatectomy or gastrectomy—1 to 2 tablets taken at 2-hour intervals, or as directed by physician.

Caution: Federal law prohibits dispensing without prescription.

Warnings: Avoid inhalation of powder.

Precautions: Use with caution in patients known to be allergic to pork protein.

How Supplied:

Powder: Bottles of 4 ounces and 8 ounces

Tablets: Bottles of 100 and 500

Literature Available: Complete literature available upon request including information on BEEF VIOKASE DERIVED FROM BEEF PANCREAS FOR THOSE EXCEPTIONAL PATIENTS ALLERGIC TO PORK.

VIOBIN

VIOBIN CORPORATION
A Subsidiary of A.H. Robins Company
Monticello, IL 61856